Andrew R. Boll
2018
In 2018, Andrew R. Boll earned a total compensation of $551.2K as Chief Financial Officer at Imprimis Pharmaceuticals, a 5% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,900 |
|---|---|
| Option Awards | $68,000 |
| Salary | $264,631 |
| Stock Awards | $2,175 |
| Other | $12,496 |
| Total | $551,202 |
Boll received $264.6K in salary, accounting for 48% of the total pay in 2018.
Boll also received $203.9K in non-equity incentive plan, $68K in option awards, $2.2K in stock awards and $12.5K in other compensation.
Rankings
In 2018, Andrew R. Boll's compensation ranked 11,557th out of 14,244 executives tracked by ExecPay. In other words, Boll earned more than 18.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,557 out of 14,244 | 19th |
Division Manufacturing | 4,668 out of 5,762 | 19th |
Major group Chemicals And Allied Products | 1,769 out of 2,125 | 17th |
Industry group Drugs | 1,505 out of 1,814 | 17th |
Industry Pharmaceutical Preparations | 1,156 out of 1,388 | 17th |
Source: SEC filing on April 25, 2019.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2018.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019